MET and non-small cell lung carcinoma: Multiple kinase inhibitors (MKIs) were found to have significant effects on RET, vascular endothelial growth factor receptor-2(VEGFR2), The hepatocyte growth factor receptor (MET), The Multiple targets of tyrosine kinase, such as epidermal growth factor receptor (EGFR), have inhibitory effects [11], and are first used for molecular targeted therapy of advanced RET fusion-positive NSCLC.